Literature DB >> 21492943

T cell deficiency does not reduce lesions in mice produced by intracerebral injection of NMO-IgG and complement.

Samira Saadoun1, Patrick Waters, Claire Macdonald, Leslie R Bridges, B Anthony Bell, Angela Vincent, A S Verkman, Marios C Papadopoulos.   

Abstract

We reported recently that intracerebral administration of NMO-IgG with human complement produces neuromyelitis optica (NMO) lesions in mice. We examined the role of T cells in the formation of NMO lesions by comparing brain histopathology in wildtype and nude mice. Brains were co-injected with IgG from NMO patients and human complement. At 24h and 5days, wildtype vs. nude mouse brains had comparable inflammation (CD45 immunoreactivity), loss of myelin (Luxol Fast Blue staining) and loss of AQP4 immunoreactivity. We conclude that T cells are not required for the formation of NMO lesions in this mouse model.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21492943     DOI: 10.1016/j.jneuroim.2011.03.007

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  21 in total

1.  Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain.

Authors:  Samira Saadoun; Patrick Waters; Claire MacDonald; B Anthony Bell; Angela Vincent; A S Verkman; Marios C Papadopoulos
Journal:  Ann Neurol       Date:  2012-02-28       Impact factor: 10.422

Review 2.  Aquaporin 4 and neuromyelitis optica.

Authors:  Marios C Papadopoulos; A S Verkman
Journal:  Lancet Neurol       Date:  2012-05-16       Impact factor: 44.182

3.  Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica.

Authors:  Lukmanee Tradtrantip; Hua Zhang; Samira Saadoun; Puay-Wah Phuan; Chiwah Lam; Marios C Papadopoulos; Jeffrey L Bennett; A S Verkman
Journal:  Ann Neurol       Date:  2012-01-23       Impact factor: 10.422

4.  Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more.

Authors:  Marie Cathrin Mayer; Edgar Meinl
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

5.  Optic neuritis in neuromyelitis optica.

Authors:  Marc H Levin; Jeffrey L Bennett; A S Verkman
Journal:  Prog Retin Eye Res       Date:  2013-03-30       Impact factor: 21.198

Review 6.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

7.  Blood-brain barrier resealing in neuromyelitis optica occurs independently of astrocyte regeneration.

Authors:  Anne Winkler; Claudia Wrzos; Michael Haberl; Marie-Theres Weil; Ming Gao; Wiebke Möbius; Francesca Odoardi; Dietmar R Thal; Mayland Chang; Ghislain Opdenakker; Jeffrey L Bennett; Stefan Nessler; Christine Stadelmann
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

Review 8.  Experimental models of neuromyelitis optica: current status, challenges and future directions.

Authors:  Minshu Li; Yaping Yan
Journal:  Neurosci Bull       Date:  2015-06-24       Impact factor: 5.203

9.  Review of Animal Models of Neuromyelitis Optica.

Authors:  Melina V Jones; Nicolas Collongues; Jerome de Seze; Makoto Kinoshita; Yuji Nakatsuji; Michael Levy
Journal:  Mult Scler Relat Disord       Date:  2012-10       Impact factor: 4.339

10.  Unique neuromyelitis optica pathology produced in naïve rats by intracerebral administration of NMO-IgG.

Authors:  Nithi Asavapanumas; Julien Ratelade; A S Verkman
Journal:  Acta Neuropathol       Date:  2013-11-05       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.